HD-OPM Archive
Topics › Brain health & dementia

Low-dose lithium carbonate failed to slow cognitive decline in mild cognitive impairment

Louis Nervegna · Mar 02, 2026 · ♥ 3 reactions · 2 comments · original Facebook post
Brain health & dementiaSupplements & vitamins
AI summary & key facts

A JAMA Neurology RCT found low-dose lithium did not significantly delay cognitive decline or change imaging and plasma biomarkers over 2 years in older adults with MCI, though it was safe. Louis notes the trial used lithium carbonate, whereas Yankner's Harvard work suggests lithium orotate is the active form in Alzheimer's models.

Low dose lithium carbonate failed to delay progression of cognitive decline in patients with mild cognitive impairment (MCI) likely to progress to Alzheimer’s.

The results of this RCT were just published.

My note:

It’s very possible that they used the wrong form of lithium in this trial. We now know from Bruce Yankner’s recently published work at Harvard that it is the orotate form of lithium that has significant activity in Alzheimer’s models, not the carbonate form. Yankner predicted that the carbonate form would not work well. (Refer to comments section for more on this.)

See these previous posts on Yankner’s work:

↪ Harvard study ties lithium deficiency to Alzheimer's disease in mice and humans

↪ Human trials of lithium orotate for Alzheimer's to start spring 2026 at MGH/Brigham

↪ Harvard begins clinical trials of low-dose lithium for Alzheimer's

#lithiumHD #alzheimersHD #dementiaHD

Research cited

Among older adults with mild cognitive impairment, low-dose lithium did not significantly delay cognitive decline or affect neuroimaging and plasma biomarker outcomes over 2 years. Treatment was safe and well tolerated.

Paper · JAMA Neurol · 2026Low-Dose Lithium for Mild Cognitive ImpairmentImportance Lithium deficiency may contribute to Alzheimer disease pathogenesis. No randomized clinical trial has examined lithium’s effects on cognition, neuroimaging, and plasma biomarkers in mild cognitive impairment (MCI). Objective To examine the feasibility, safety, and preliminary efficacy of lithium carbonate for delaying cognitive decline in older adults with MCI. Design, Setting, and Participants This…jamanetwork.comNo photo description available.
← newer: Statin plaque regression: one case report and six trials shoolder: Six randomized trials show statins reduce total plaque volum →